logo
Donate Create or log into HDSA Account
  • About HDSA
  • News
  • Events
  • Advocacy
  • Chapters & Affiliates
  • HDSA Centers of Excellence
  • HDSA’s NYA
  • PUBLICATIONS
  • What is
    HD?
    • What Is HD?

      Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain.  It deteriorates a person’s physical and mental abilities usually during their prime working years and has no cure.

      • History and Genetics of Huntington’s Disease
      • Overview of HD
      • Who Is At-Risk?
      • Genetic Testing & Family Planning
      • Juvenile Onset HD
      • History of HD
      • Huntington’s Disease Symptoms
      • The Age of Onset
      • Motor / Physical Symptoms
      • Cognitive Symptoms
      • Behavioral / Psychological Symptoms
      • Stages of Huntington’s Disease
      • Early Stage
      • Middle Stage
      • Late Stage
  • Find
    Help
    • Find Help

      Locate HDSA Chapters and Affiliates, Support Groups, Social Workers, and Centers of Excellence in your area as well as additional local medical, legal, social, and therapeutic resources for people with HD and their families.

      • LOCATE RESOURCES IN YOUR AREA
      • Clinical Care & Services
      • HDSA Centers of Excellence
      • Symptom Management
      • Suicide Prevention
      • Healthcare & Future Planning
      • Genetic Testing & Your Rights
      • Disability Benefits and HD
      • Long-Term HD Care
      • Living Well With HD
      • Nutrition
      • Exercise / Physical Therapy
      • Swallow Dysfunction & Choking
      • Speech
      • Law Enforcement Training Guide
      • Community & Social Support
      • Youth Services
      • Caregiver Services & Resources
      • HDSA Telehealth
      • HDSA Support Groups
      • HDSA Social Workers
      • HDSA Resource Library
  • HD
    Research
    • HD Research

      Since 1999, the Huntington’s Disease Society of America has committed more than $20 million to fund research, with the goal of finding effective treatments to slow Huntington’s disease. Our research efforts have helped to increase the number of scientists working on HD and have shed light on many of the complex biological mechanisms involved.

      • Participate in HD Research
      • HD Trialfinder
      • Participate in Online Surveys
      • Enroll-HD
      • Learn About HD Research
      • This Week In HD Research Blog
      • HDSA Research Webinars
      • HDBuzz
      • Annual HDSA Research Reports
      • HD Research in the Pipeline
      • HDSA Research Funding Programs
      • HD Human Biology Project
      • Donald A. King Fellowship
      • Berman-Topper Fellowship
      • Spotlight on HD Researchers
      • HD Cope
      • Scientific Advisory Board
  • Healthcare
    Professional Resources
    • Healthcare Professional resources

      This section includes online courses for physicians, social workers and therapists who care for people with HD at the local level. Courses deal with cognitive, physical, therapeutic, technological and legal HD issues among other topics. This section also includes reference materials in video and PDF format for Social Workers on HD issues listed by varied categories.

      • HD 101: CME SERIES
      • SOCIAL WORKER CONTINUING EDUCATION
      • RESOURCES FOR PHYSICAL THERAPISTS
      • PT CONTINUING EDUCATION
      • RESOURCES FOR SOCIAL WORKERS
      • OT CONTINUING EDUCATION
      • GENETIC COUNSELORS CONTINUING EDUCATION
  • Get
    Involved
    • GET INVOLVED

      When Marjorie Guthrie founded our organization in 1967, her vow was to “do something” about this devastating disease. Today we continue her legacy by bringing together the entire community to provide help and hope to all families affected by Huntington’s disease. Listed here are some of the ways you can get involved in the fight against HD.

      • DONATION OPPORTUNITIES
      • One-Time Donation
      • Monthly Giving
      • Tribute & Memorial Donations
      • Stocks / Assets / Real Estate
      • Planned Giving
      • Matching Gifts Program
      • Workplace Giving
      • Vehicle Donations
      • HDSA Tree of Help & Hope
      • HDSA Family Funds
      • Sweepstakes
      • Corporate Partnerships
      • Volunteer Opportunities
      • Volunteer Registration
      • HDSA New York City Marathon
      • HD ADVOCACY
      • Team Hope Walk Program
      • HDSA Events
      • HDSA Shop
      • HDSA Gear
      • Flowers for HDSA
      • Publications
      • Shop HDSA Partners
  • news
  • Email
  • Like
  • Tweet

News

Archives

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • BLOG: This Week in HD Research
  • BLOG: Disability Tips
  • The HDSA Podcast Episode #2
  • Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
  • HDBuzz: Roche Phase II GENERATION HD2 study underway
  • Huntington’s Disease Society of America Awards More Than $2 Million To Expand HDSA Centers of Excellence Network to Sixty-Seven Sites Across the US
  • Louise Vetter provides statement in support of the FDA Listening Session on Juvenile Onset Huntington’s Disease
  • HDSA Publishes 2022 Year in Review Magazine
  • Introducing The HDSA Podcast
  • Roche-Genentech Community Letter: GENERATION HD2 study now open
  • 38th Annual HDSA Convention in New Orleans Registration Now Open
  • The Marker: HDSA’s 2022 Research Report is now available
  • HDSA Community Statement: FY23 Omnibus Appropriations Package Fails HD Families 
  • HDBuzz: Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
  • Novartis provides status of VIBRANT-HD, the study of branaplam/LMI070 in Huntington’s disease
  • Teresa Srajer Appointed Chair of HDSA’s National Board of Trustees
  • Team HDSA Raises More Than $100,000 at the New York City Marathon
  • HDSA Earns Four-Star Rating From Charity Navigator
  • Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine
  • HDSA Awards $886,785 to Huntington’s Disease Human Biology Projects
  • Breaking News: uniQure provides update on AMT-130
  • Eighth Annual Freeze HD Raises More Than $200,000
  • PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
  • Three-year study shows that AUSTEDO® is safe, tolerable, and controls chorea in people with HD
  • HDSA Publishes 2021 Annual Report
  • HDBuzz: Forward momentum for Roche & Wave in latest news about huntingtin-lowering trials
  • Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial
  • BREAKING NEWS: Roche/Genentech Announce Plans For GENERATION-HD2
  • HDSA Disability Chat: JHD & Social Security
  • HDSA Research Webinar: All You Need To Know About PROOF-HD
  • HDBuzz: Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
  • Novartis Provides Community Update Regarding VIBRANT-HD
  • HDSA Research Webinar: HD Clinical Trials Update
  • Now Accepting 2023 HDSA Centers of Excellence Letters of Intent
  • Sage Therapeutics Provides Positive Update on the SURVEYOR Study
  • HDSA Films presents KING’S CRUSADE (Part 2)
  • HDSA Statement Regarding VIBRANT-HD Trial
  • uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
  • HDSA Films presents KING’S CRUSADE (Part 1)
  • Highlights from CHDI’s 17th Annual Huntington’s Disease Therapeutics Conference
  • HDSA Awards 2022 Berman-Topper Family HD Career Development Fellowship
  • uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
  • HDBuzz: How clever computers are helping us understand Huntington’s disease
  • New system that defines Huntington’s disease will ‘revolutionise’ drug trials
  • HDBuzz: A new roadmap to track Huntington’s disease progression
  • 37th Annual HDSA Convention In Atlanta Brings The Global Huntington’s Disease Community Together Again
  • Annexon Biosciences announces positive results from a Phase 2 clinical trial evaluating ANX005 in people with HD
  • HDSA Films presents THE STORY OF E.J. + KATY
  • HDSA Wins 2022 HD Hockey Classic & Raises More Than $15,000
  • HDSA Announces Winners of the 2022 Donald A. King Summer Research Fellowship
  • PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington’s Disease
  • HDBuzz: A spoonful of branaplam helps the huntingtin go down
  • HDBuzz: Day 3 of the 2022 HD Therapeutics Conference
  • HDBuzz: Day 2 of the 2022 HD Therapeutics Conference
  • HDBuzz: Day 1 of the 2022 HD Therapeutics Conference
  • Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage’s Investigational Drug, SAGE-718.
  • HDBuzz: Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
  • Huntington’s Disease Society of America Awards Nearly $1.9 Million to Network of Fifty-Five HDSA Centers Of Excellence
  • uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
  • HDBuzz: Oral drug may change the story for huntingtin lowering
  • Register Today for the 37th Annual HDSA Convention in Atlanta
  • HDSA Publishes 2021 Year In Review Magazine
  • BREAKING NEWS: Novartis Provides Community Update On The Status Of The VIBRANT-HD Trial
  • VIDEO: Roche Community Presentation of New Tominersen Data
  • BREAKING NEWS: Roche Has Announced That The Tominersen Research Programme Will Continue With A New Phase II Trial
  • Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment
  • VIDEO: Happy Holidays from Louise Vetter
  • uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
  • The Marker is Now Available! Read HDSA’s 2021 Research Report
  • Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington’s Disease
  • Dr. Jeff Carroll & Dr. Beth Hoffman Join HDSA’s National Board of Trustees
  • HDSA Coffee Walk with Jennifer Simpson
  • TAKE ACTION: HDSA’s 7 Days of Action
  • HDSA Films presents THE DOHERTYS: FINDING THE FUNNY
  • HDSA Applauds Chairman Neal on Inclusion of Paid Family & Medical Leave in Build Back Better Act
  • More than $64,000 Raised at the TCS New York City Marathon to Support HDSA
  • HDSA Welcomes Dr. Arik Johnson as New Chief Mission Officer 
  • Virtual 7th Annual Freeze HD Raises More Than $211,000 To Support The Fight Against Huntington’s Disease
  • HDSA Awards $749,000 to HD Human Biology Projects
  • HDBuzz: Q&A with Roche about GENERATION-HD1
  • HDSA Publishes 2020 Annual Report
  • Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
  • Community Statement from Roche-Genentech Regarding GENERATION-HD1 Data
  • HDBuzz: Creation of a molecular “dimmer switch” advances gene editing
  • HDBuzz: Unpacking Recent Gene Therapy Press
  • Update from Voyager Therapeutics
  • HDSA Films Presents The Osborns: Our Legacy
  • VIDEO: Watch Kala Booth Discuss Huntington’s Disease & the HD Parity Act In Front of Congress
  • HDSA Applauds E&C Subcommittee for Highlighting Burden of Huntington’s Disease, Reiterates Call to Pass Bipartisan HD Parity Act
  • HDBuzz: A First For CRISPR Gene Editing Could Have Wider Applications For Human Disease
  • NOW AVAILABLE: Virtual 36th Annual HDSA Convention Recorded Sessions
  • Virtual 36th Annual HDSA Convention Welcomes Thousands from Around the Globe
  • HDSA Awards Two Berman-Topper Family HD Career Development Fellowships
  • HDSA Partners with PatientsLikeMe to Create an Integrated Online Community for both Patients & Caregivers
  • uniQure’s AMT-130 for Treatment of Huntington’s Disease Advances in Phase I/II Clinical Trial
  • HDSA RESEARCH WEBINAR: Roche Presents GENERATION-HD1 Data
  • HDBuzz: Day 3 Recap from the 2021 HD Therapeutics Conference
  • HDBuzz: Day 2 Recap from the 2021 HD Therapeutics Conference
  • HDBuzz: Day 1 Recap from the 2021 HD Therapeutics Conference
  • HDSA Announces Winners of 2021 Donald A. King Summer Research Fellowship
  • Now Accepting 2021 National Award Nominations
  • uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130
  • Register Today For Free | Virtual 36th Annual HDSA Convention
  • HDBuzz: Wave Life Sciences PRECISION-HD Trials
  • Disappointing Update from Wave Regarding PRECISION-HD Clinical Trials
  • VIDEO: A Message from Roche about the GENERATION-HD1 Trial News
  • RESEARCH WEBINAR | Generation-HD1 Trial News: What does this mean and where do we go from here?
  • HDBuzz: Sad News From Roche
  • Roche Provides a Disappointing Update on Tominersen
  • HDSA Reintroduces the HD Parity Act
  • HDSA Films presents My Father, My Hero
  • Now Accepting 2021 Human Biology Project Letters of Intent
  • HDBuzz: Vaccines and HD
  • The 36th Annual HDSA Convention Goes Virtual!
  • HDSA Expands Centers of Excellence Program to Fifty-Four Sites
  • HDSA Publishes 2020 Year In Review Magazine
  • Dr. Victor Sung Named Chair of HDSA’s National Board of Trustees
  • Happy New Year!
  • NEW EPISODE: Here’s The Deal with Dick Johnson Is Dead
  • HDSA Publishes The Marker: 2020 Research Report
  • HDSA Awards Four HD Human Biology Project Fellowships For 2020
  • HDBUZZ: Updates from the EHDN Plenary Meeting 2020
  • VIRTUAL 6TH ANNUAL FREEZE HD RAISES $200,000 FOR HDSA
  • HDSA Publishes 2019 Annual Report
  • HDBuzz: When genes are unstable: Targeting somatic instability in HD
  • NEW EPISODE: Here’s The Deal with Talking to Kids about Huntington’s Disease
  • HDBuzz: Changes In Brain Development Mean Some Brain Regions May Be Slacking Off
  • HDBuzz: Caution Urged for the Use of Gene-Editing Technology CRISPR
  • Anne Leserman announces her retirement from HDSA
  • Submit Your Letter of Interest to Become a 2021 HDSA Center of Excellence
  • NEW EPISODE: Here’s The Deal with End of Life & HD
  • Huntington’s Disease Featured on ABC News Live Prime
  • HDSA Center of Excellence at Ohio State Conducts First Gene Therapy Clinical Trial for HD
  • uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
  • Virtual HDSA Convention Recorded Sessions Now Available
  • Virtual 35th Annual HDSA Convention Welcomes Thousands from Across the Globe 
  • HDSA Supports The Fight Against Racism
  • Register for the Virtual 35th Annual HDSA Convention
  • Postcard from Palm Springs: Highlights from the 2020 CHDI HD Therapeutics Conference
  • HDSA Awards Berman-Topper Family HD Career Development Fellowship
  • International Huntington’s Disease Awareness Day – May 15th
  • HDSA Announces Winners of 2020 Donald A. King Summer Research Fellowship
  • COMMUNITY STATEMENT: Update On Tominersen (RG6042)
  • NEW EPISODE: Here’s The Deal with Self-Care
  • HDBuzz: What does COVID-19 mean for Huntington’s disease families and HD research?
  • HD & COVID-19 PANDEMIC RESOURCES
  • NEW EPISODE: Here’s The Deal with COVID-19 & HD
  • FREQUENTLY ASKED QUESTIONS: Disability & COVID-19
  • Community Statement
  • NEW EPISODE: Here’s The Deal with Disability
  • HDSA Community Update: HDSA’s 35th Annual Convention Goes Virtual!
  • HDSA Community Update: HD & COVID-19
  • HDSA Community Update
  • HDBuzz: New Molecule Can Reverse The Huntington’s Disease Mutation In Lab Models
  • HDSA Convention Community Statement
  • HDBuzz: Day 3 at HD Therapeutics Conference
  • HDSA Films Presents ALLIE & JOE
  • HDBuzz: Day 2 at HD Therapeutics Conference
  • HDBuzz: Day 1 at HD Therapeutics Conference
  • HDSA Announces Fifty 2020 Centers of Excellence
  • HDSA Publishes 2019 Year In Review Magazine
  • REGISTER TODAY! 35th Annual HDSA Convention in New Orleans
  • Community Letter from Wave Life Sciences Regarding Topline Results from PRECISION-HD2
  • Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
  • HDSA Earns Fourth Consecutive 4-Star Rating From Charity Navigator
  • HDSA Awards Inaugural Clinical Research Pilot Grants to Four Centers of Excellence
  • HDSA Listed As Top 10 Volunteer Opportunities In New York City By Great Nonprofits
  • HDSA Welcomes Three Trustees to National Board
  • HDSA Publishes The Marker – 2019 Research Report
  • HDSA’s New York City Marathon Team Raises More Than $133,000 To Support The Fight Against HD
  • HDSA Awards Five 2019 HD Human Biology Project Fellowships
  • Community Statement from Roche / Genentech
  • View 5th Annual Freeze HD Red Carpet and Event Photos
  • 5th Annual Freeze HD Raises More Than $420,000 To Support HDSA
  • 2018 HDSA Annual Report
  • HDBUZZ: Exciting New Huntingtin Lowering Tool Described
  • Now Accepting 2020 HDSA Centers of Excellence Letters of Interest
  • VIDEO: Here’s The Deal With Caregiving While Positive
  • VIDEO: 34th Annual HDSA Convention Recap
  • HDSA Sets New Attendance Record at the 34th Annual HDSA Convention in Boston
  • Community Statement from uniQure
  • HDSA & CHDI Foundation Launch HD Legacy to Promote Brain Donation for HD Research
  • HDSA Adds Allison Bartlett as Manager of Disability Programs
  • HDSA Awards 2019 Berman-Topper Family HD Career Development Fellowships
  • Huntington’s Disease Parity Act Is Reintroduced
  • HDBUZZ: Fresh Updates from First Huntingtin Lowering Study Publication
  • Postcard from Palm Springs: Highlights from the 2019 CHDI HD Therapeutics Conference
  • HDSA Announces Winners of 2019 Donald A. King Summer Research Fellowship
  • HDSA Films Presents “The Hodgsons” Short Film
  • Update on PRECISION-HD program
  • BLOG: This Week in HD Research
  • HDBUZZ: An Updated Trial Design for Roche’s Huntingtin Lowering Trial: Roche announces an update to the GENERATION HD1 trial after reviewing the ASO open label extension study
  • COMMUNITY STATEMENT FROM ROCHE/GENENTECH: Amendment to the RG6042 Phase III GENERATION HD1 study design
  • HDBUZZ: Genetic Hiccups That Protect Against Huntington’s Disease
  • HDBUZZ: Huntington’s Disease Therapeutics Conference 2019 – Day 3 Recap
  • HDBUZZ: Huntington’s Disease Therapeutics Conference 2019 – Day 2 Recap
  • Huntington’s Disease Featured On The Today Show
  • HDSA Expands Centers of Excellence Program to Forty-Seven
  • HDBuzz: Huntington’s Disease Goes Viral as uniQure Inches Ahead in Gene Therapy Race
  • First Patients Enrolled in HD Natural History & GENERATION HD1 Clinical Studies
  • HDSA Publishes 2018 Year In Review Magazine
  • uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
  • HDSA Launches Youth Social Worker Program
  • BREAKING NEWS: Roche/Genentech Announces US Locations of GENERATION-HD1 Drug Study
  • HDSA’s 2018 Research Report Now Available
  • EJ Garner Appointed as Chair of HDSA’s National Board of Trustees
  • HDBUZZ: Advances on many fronts in the battle against the protein that causes Huntington’s disease
  • Genentech/Roche Announces US & Canadian Locations of Observational Natural History Study
  • HDSA Awards Five HD Human Biology Project Fellowships for 2018
  • FAQs: Upcoming Genentech/Roche Studies
  • HDBuzz: Kids Get Huntington’s Disease Too
  • RESEARCH WEBINAR: Update from Roche/Genentech on GENERATION-HD1 & RG6042
  • HDBuzz: The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington’s disease
  • Update on RG6042 (formerly known as IONIS-HTTRx) Huntington’s disease global development programme: Two clinical studies to begin by end of 2018
  • Roche’s Phase 3 Trial for RG6042 (formerly IONIS HTT-Rx) has been announced: GENERATION-HD1
  • Roche Media Release Regarding PRIME Designation Granted by European Medicines Agency for RG6042 (formerly IONIS-HTT Rx)
  • IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington’s Disease
  • Now Accepting 2019 HDSA Centers of Excellence Letters of Interest
  • HDBUZZ: First Dolly, now Piglet; a new Huntington’s disease pig knock-in model confirmed
  • VIDEO: 33rd Annual HDSA Convention Recap
  • 33rd Annual HDSA Convention Recap
  • VIDEO: HD Buzz at the 33rd Annual HDSA Convention
  • VIDEO: 33rd Annual HDSA Convention Research Forum
  • VIDEO: 33rd Annual HDSA Convention Opening Ceremony
  • Getting to know Roche & Genentech, RG6042 (formerly known as IONIS-HTTRx )
  • HDSA Awards Berman-Topper Family HD Career Development Fellowship
  • FAQs Regarding the Latest Huntingtin-Lowering Update from Ionis & Roche
  • New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington’s Disease
  • HDSA Announces Winners of 2018 Donald A. King Summer Research Fellowship
  • Roche Community Statement Regarding RG6042 (formerly known as IONIS-HTTRx )
  • HDBuzz: Exciting Experiments in “Open Science” by Huntington’s Researchers
  • VIDEO: Postcard from CHDI Meetings in Palm Springs & Malta
  • HDSA Partners with the ALS Association & Teva Pharmaceuticals to Identify Novel Therapeutic Targets for CNS Disorders
  • HDSA Earns Second Consecutive 4-Star Rating from Charity Navigator
  • HDBUZZ: Huntington’s disease therapeutics conference 2018 – day 3
  • IONIS-HTT Rx Community Statement
  • IONIS-HTT Rx : Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington’s Disease
  • HDBUZZ: Huntington’s disease therapeutics conference 2018 – day 2
  • HDBUZZ- Huntington’s disease therapeutics conference 2018 – day 1
  • HDSA Announces Forty-Three Centers of Excellence
  • CEO Memo: Chorea Medication Co-Pay Assistance Programs Information
  • FAQs: Ionis Huntingtin-Lowering Trial
  • Statement by Louise Vetter, President & CEO of the Huntington’s Disease Society of America regarding Ionis-HTTRx Announcement
  • BREAKING NEWS: Update on the Status of the IONIS-HTTRx Program and its Future
  • Huntington’s Disease Society of America Announces the Launch of a Three-Part Online Accredited Continuing Education Course for Community Based Primary Care Providers, Neurologists and Psychiatrists
  • HDSA Honors Sportscaster Chris Berman & Raises More Than $250,000
  • HDSA Pays Tribute to Founder Marjorie Guthrie & 50 Years of the Guthrie Family Legacy
  • HDBUZZ: Switch off the genome editor when you’re done
  • Update confirms Huntington’s disease ‘gene silencing’ trial on track
  • Huntington’s Disease Society of America Awards Four HD Human Biology Project Fellowships for 2017
  • HDBUZZ: New roles for huntingtin: removing a healthy protein to understand its function
  • Global Huntington’s Disease Patient Advocacy Organizations Unite to Form Huntington’s Disease Coalition for Patient Engagement (HD-COPE)
  • Huntington’s Disease Society of America’s 50th Anniversary to Celebrate the Life & Legacy of Its Founder Marjorie Guthrie
  • HealthWell Foundation Opens Huntington’s Disease Fund to Assist Medicare Patients
  • HDBUZZ: A step forward for gene editing: CRISPR-Cas9 and HD
  • Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
  • Exclusive HDBuzz interview with Prof Lesley Jones (Cardiff University) and Prof Sarah Tabrizi (University College London) about their new paper describing a ‘genetic modifier’ for Huntington’s disease.
  • Exciting News: IONIS provides update on Huntingtin lowering trial
  • HUNTINGTON’S DISEASE SOCIETY OF AMERICA LAUNCHES FIRST-OF-ITS-KIND FREE TELEHEALTH COUNSELING FOR HD FAMILIES
  • New study reveals a potential HD biomarker
  • HUNTINGTON’S DISEASE SOCIETY OF AMERICA AWARDS BERMAN-TOPPER FAMILY HD CAREER DEVELOPMENT FELLOWSHIPS RESEARCHERS FROM CALIFORNIA AND CANADA AWARDED PRESTIGIOUS GRANT
  • Huntington’s Disease Parity Act Reintroduced to Waive Two-Year Waiting Period for Medicare Coverage for those with Huntington’s Disease
  • Huntington’s Disease Society of America Raises Nearly $40,000 at Guthrie Sessions Live in New York City
  • Huntington’s Disease Society of America Announces Winners of 2017 Donald A. King Summer Research Fellowship
  • Huntington’s Disease Society of America Premieres Her Mother’s Daughter Documentary During HD Awareness Month
  • Has a “wonder drug” for dementia been discovered? (Spoiler alert: no.)
  • Huntington’s Disease Society of America Collaborates with HealthWell Foundation to Launch Movement Disorders Fund to Provide Financial Assistance to Medicare Patients
  • Huntington’s Disease Therapeutics Conference 2017 – Day 3
  • Huntington’s Disease Therapeutics Conference 2017 – Day 2
  • Huntington’s Disease Therapeutics Conference 2017 – Day 1
  • Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
  • Pope Francis To Meet With The Global Huntington’s Community To Shine A Light On And Lift Stigma Of Disease
  • HDBuzz article – FDA approves a new drug for symptoms of Huntington’s disease
  • Sheep can help us to identify HD biomarkers and recognize metabolic changes that occur before symptoms develop.
  • 2017 National Awards Nominations
  • Save the Date- For the largest global gathering of the HD community!
  • Huntington’s Disease Society of America Announces Premiere for Juvenile Huntington’s Disease Documentary
  • Weeding out the truth: can cannabis improve Huntington’s?
  • Huntingtin grabs a hammer: DNA repair in HD
  • The benefits of migration, highlighted in Huntington’s disease
  • Huntington’s Disease Society of America Announces Forty-One 2017 HDSA Centers of Excellence
  • Huntington’s Disease Society of America Unveils HDNavigator Mobile App
  • HDBuzz: Treasure your exceptions – using outliers to understand Huntington’s disease onset and progression
  • Pfizer Amaryllis trial ends : no improvement in Huntington’s disease symptoms
  • HDSA has published the 2016 Research Report which provides in-depth Huntington’s disease research information and highlights from 2016.
  • Huntington’s Disease Society of America to Provide 1,000 Free Liftware Level Devices to People Living with Huntington’s Disease
  • HDSA Earns Top-Rating from CharityWatch
  • Huntington’s Disease Society of America AWARDS $930,000 to nine new HD Human Biology fellows
  • Important advances in next generation genome editing tools for Huntington’s Disease
  • HDBuzz helps untangle the results of the PRIDE-HD trial of pridopidine
  • EuroBuzz 2016: The Euro-HD Network Meeting in The Hague
  • Exciting Press Release from Teva Regarding Pridopidine: Possibly the first disease modifying drug for HD
  • New technology enables researchers to find ultra-rare mutations in the HD gene, distinct from the one causing HD
  • HD Support & Care Network and Huntington’s Disease Society of America Partner for Stronger HD Support Groups in California and Arizona
  • Deutetrabenazine for Huntington’s disease: a positive trial but the FDA says no? Not exactly…
  • A support system gone wrong – glial cells contribute to HD symptoms
  • Huntington’s Disease Society of America’s 2017 HDSA Center of Excellence Program Now Accepting Letters of Interest
  • Huntington’s Disease Community Scores Major Victory with Social Security Criteria
  • Slightly long CAG repeats are more common than we thought
  • Early exposure to the HD protein may cause life-long symptoms
  • WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
  • Electron beam snaps best images yet of Huntington’s disease protein
  • Select Videos From HDSA’s 31st Annual Convention Now Available
  • Huntington’s Disease Society of America Hosts the 2nd Largest Convention in 31 Years
  • Huntingtin takes a trip: harmful proteins pass between brain cells
  • Watch us Live from the 31st Annual HDSA Convention
  • HDSA National Board of Trustees is asking for your help developing a new five-year plan that will chart the organization’s goals from 2017-2021.
  • Postcard from Palm Springs
  • Huntington’s Disease Society of America awards first-ever Berman-topper Family HD Career Development Fellowship
  • Important drug targets yielded by new genetic study of HD
  • Huntington’s Disease Society of America Launches #LetsTalkAboutHD Campaign During Huntington’s Disease Awareness Month in May
  • Huntington’s Disease Society of America Releases Updated “Genetic Testing Protocol for Huntington’s Disease”
  • Thinking clearly about the earliest symptoms of HD and which brain regions control them
  • Huntington’s Disease Society of America Announces Winners of 2016 Donald A. King Summer Research Fellowship
  • 2016 HDSA NATIONAL AWARDS NOMINATIONS
  • How NOT to write a news article about a clinical trial
  • HDBuzz article – Huntington’s Disease Therapeutics Conference 2016 – day 3
  • HDBuzz article – Huntington’s Disease Therapeutics Conference 2016 – day 2
  • HDBuzz article – Huntington’s Disease Therapeutics Conference 2016 – day 1
  • Huntington’s Disease Society of America Partners with WeHaveAFace.org to Increase Access to The Huntington’s Disease Project: Removing the Mask
  • Huntington’s Disease Society of America Announces Thirty-Nine 2016 HDSA Centers of Excellence
  • Harnessing the power of viruses to treat Huntington’s disease
  • Through a Broader Lens: Looking at Non-Motor Symptoms in HD
  • HDSA Releases 2015 Year in Review
  • HDSA Releases 2015 Research Investor’s Report
  • Looking Past the Spin: Results from a Clinical Trial of Cysteamine
  • An existing drug could give a boost to HD brain cells – but it may need more testing before it’s back in the clinic
  • Raptor Plans to Advance RP103 in a Registration Study
  • New HD Career Development Fellowship Announced by Huntington’s Disease Society of America
  • Through the eyes of a friend: changes in mood and behavior in early HD
  • Huntington’s Disease Society of America Adds Call Center Component to HD TrialFinder
  • Huntington’s Disease Society of America Receives 4-Star Rating From Charity Navigator
  • A multiple sclerosis drug that works for Huntington’s disease: the real deal or too good to be true?
  • Huntington’s Disease Society of America Now Accepting Applications for the 2016 Donald A. King Summer Research Fellowship
  • Huntington’s Disease Society of America’s New York City Marathon Team Raises More Than $125,000
  • Fourth Annual Strike Out HD Bowling Event Hosted by New York Giant Geoff Schwartz Raises Nearly $50,000
  • HDBuzz- Liftoff: First humans treated with gene silencing drugs for HD!
  • HDBuzz primer: Clinical trial designs and phases
  • Huntington’s Disease Society of America Announces 2015 HD Human Biology Project Grant Recipients
  • FDA Opens 60 Day Open Comment Period
  • Hundreds of HD Families Join FDA Hearing to Shape Drug Development for Huntington’s Disease
  • HDBUZZ- A Few Bad Seeds: Using Brain Fluid to Grow Clumps in Brain Cells
  • CNN “NEW DAY” Hosts Alisyn Camerota & Chris Cuomo raise $10,000 for the Huntington’s Disease Society of America
  • Deadline To Tell Us Your Thoughts Has Been Extended!
  • HDSA Announces 2016 Call for Letters of Interest for Center of Excellence Program
  • Patient-Focused Drug Discovery Meeting at the FDA on Huntington’s Disease
  • Scientists identify genetic factors that alter the clinical onset of HD in landmark study
  • Would ewe believe it? GM1, sheep and Huntington’s disease
  • ISIS Pharmaceuticals Initiates Clinical Study of Huntingtin Lowering Drug in HD Patients
  • 30th Annual Convention is a Huge Success for the Huntington’s Disease Society of America
  • Calling all HD families: Our time to be heard is now!
  • Huntington’s Disease Society Of America Receives CHARITYWATCH Top-Rated Status
  • HDSA Supports 21st Century Cures Act
  • NIH Names Walter J. Koroshetz, M.D. Director of the National Institute of Neurological Disorders and Stroke
  • Life in HD Earns Rave Reviews for the Huntington’s Disease Society of America
  • HDBUZZ: Switching it up: variety in the HD gene affects symptom onset
  • 2015 Postcard from Palm Springs
  • HDBuzz article – A faulty filter? Blood vessel changes in Huntington’s disease
  • 2015 Huntington’s Disease Therapeutics Conference and taking part in trials
  • Gene variant determines early or late onset of Huntington’s disease
  • Life in HD: A Conversation with Lisa Genova Tickets Now on Sale
  • Huntington’s Disease Society of America Announces Winners of 2015 Donald A. King Summer Research Fellowship
  • Lighting the way: A new biomarker for Huntington’s disease
  • Huntington’s Disease Society of America Launches HD TrialFinder First-Of-Its-Kind Clinical Trial Matching Service For Huntington’s Disease
  • New York Times Bestselling Author Lisa Genova to release Inside the O’Briens
  • Law Enforcement Toolkit II Webinar Now Available
  • Huntington’s Disease Society of America Announces First-Ever HD Human Biology Project Awards
  • Huntington’s Disease Society of America Endorses Enroll-HD
  • Huntington’s Disease Society of America Announces Winners of the 2014 Donald A. King Summer Research Fellowship
  • Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
  • HDSA appoints Director of Marketing & Communications
  • World leader in movement disorders Professor Ira Shoulson joins Prana Board
  • Pitt Study Demonstrates How Huntington’s Disease Protein Disrupts a Novel Cellular Pathway to Cause Death of Neurons
  • Huntington’s Disease Society of America Launches First “HD News” App
  • 2CARE HD Clinical Trial Stopped Early for Lack of Benefit
  • HDBuzz: 2CARE Study of Coenzyme Q for Huntington’s Disease Ends
  • Auspex Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of SD-809 in Chorea Associated With Huntington’s Disease (FIRST-HD)
  • Huntington’s Disease Society of America Awards Additional HD Human Biology Project
  • Jang-Ho Cha, MD, PhD Appointed Chairman of the Board of Trustees at the Huntington’s Disease Society of America
  • Global Outcomes Data and Possible New Therapies in the Huntington’s Pipeline
  • CONTACT US

    505 Eighth Avenue / Suite 902
    New York, NY 10018

    Helpline: 800-345-HDSA (4372)
    National Office: 212-242-1968
    Email: HDSAinfo@HDSA.org
    • What is HD?
    • Find Help
    • HD Research
    • Healthcare Professional Resources
    • Get Involved
    • About HDSA
    • News
    • Events
    • Chapters & Affiliates
    • HDSA Centers of Excellence
    • HDSA National Youth Alliance
    • Publications
    • HDSA Connect
    • Disclosures
    • Tax Returns & Audited Financials
    • Privacy Policy
Donate
  • Charity Navigator Four-Star Rating

© 2023 Huntington’s Disease Society of America. All rights reserved.

Contact Us

Share a link